In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for ...

More than 20 clinical trials are currently investigating JAK inhibitors for treating diseases including autoimmune/inflammatory disorders, cancer and several myeloproliferative disorders (Table 1).

JAK inhibitors, such as ruxolitinib cream and abrocitinib, present promising alternatives to existing therapies for managing moderate to severe atopic dermatitis, offering effective treatment options.

No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

Only half of patients showed clinical improvement attributed to the medication, but only one new complication occurred.

In addition to a greater risk for serious infection, patients with atopic dermatitis initiating JAK inhibitors vs Th2 cytokine inhibitors had a greater risk of Candida infections and a slightly ...

Janus kinase (JAK) inhibitors look to be a good treatment ... But SOCS1 insufficiency was only recognized 5 years ago and its ...

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

WASHINGTON -- Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA) may not have to worry so much about ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Concerns have arisen over JAK inhibitors' cardiovascular safety relative to TNF inhibitors and other biologic agents for rheumatoid arthritis. Registry data from more than 50,000 European patients ...

Ruxolitinib cream effectively reduces moderate atopic dermatitis severity, showing comparable results to oral JAK inhibitors and biologics. Phototherapy offers a cost-effective alternative to ...